SLXN
Silexion Therapeutics Corp Ordinary SharesSLXN
SLXN
About: Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
3.19% less ownership
Funds ownership: 11.95% [Q3] → 8.76% (-3.19%) [Q4]
40% less funds holding
Funds holding: 5 [Q3] → 3 (-2) [Q4]
54% less capital invested
Capital invested by funds: $613K [Q3] → $281K (-$332K) [Q4]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Research analyst outlook
We haven’t received any recent analyst ratings for SLXN.
Financial journalist opinion
Based on 3 articles about SLXN published over the past 30 days
Neutral
GlobeNewsWire
3 weeks ago
Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds
Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,221,523 of the Company's ordinary shares originally issued in January 2025 having an exercise price of $1.35 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-282932). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $3.3 million, prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about January 30, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes.
Neutral
Business Wire
3 weeks ago
PESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market
NEW YORK--(BUSINESS WIRE)---- $SLXN #biotech--PESG Research releases new market update: Silexion Therapeutics (NASDAQ: SLXN)* continues to strengthen its position in the precision oncology landscape with breakthrough preclinical data validating systemic administration of SIL-204, potentially opening new frontiers in treating KRAS-driven cancers. This development comes amid increasing industry appetite for innovative oncology assets, exemplified by recent multi-billion dollar acquisitions. Silexion's latest precli.
Neutral
GlobeNewsWire
3 weeks ago
Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
New preclinical findings provide validation for Silexion's new systemic administration approach for SIL-204, demonstrating inhibition of tumor growth in a clinically relevant orthotopic model; Further studies aim to evaluate its impact on metastases New preclinical findings provide validation for Silexion's new systemic administration approach for SIL-204, demonstrating inhibition of tumor growth in a clinically relevant orthotopic model; Further studies aim to evaluate its impact on metastases
Positive
Benzinga
1 month ago
Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies
Silexion Therapeutics Corp. SLXN revealed new preclinical results demonstrating the synergistic efficacy of its SIL-204, in combination with components of first-line chemotherapy for pancreatic cancer.
Neutral
Business Wire
1 month ago
PESG Market Update: Silexion Therapeutics' SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments
NEW YORK--(BUSINESS WIRE)---- $SLXN #Silexion--PESG Releases a Market Update - Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech advancing RNA interference (RNAi) therapies for KRAS-driven cancers, has reported compelling new preclinical data for SIL-204, its next-generation siRNA candidate. These findings reaffirm the company's innovative approach to addressing some of the most challenging cancers, including pancreatic cancer, which is marked by KRAS mutations in over 90% of cases. The newly released.
Negative
Benzinga
1 month ago
Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.1% on Thursday.
Neutral
GlobeNewsWire
1 month ago
Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering
Cayman Islands, January 15, 2025 -- Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the pricing of a public offering of an aggregate of 3,703,703 of the Company's ordinary shares (or ordinary share equivalents) and warrants to purchase up to 3,703,703 ordinary shares at a combined public offering price of $1.35 per share (or per ordinary share equivalent) and accompanying warrant. The warrants will have an exercise price of $1.35 per share, will be exercisable immediately upon issuance and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about January 17, 2025, subject to the satisfaction of customary closing conditions.
Neutral
GlobeNewsWire
1 month ago
Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies
Significant new preclinical results demonstrate synergistic activity of SIL-204 with 5-fluorouracil and irinotecan as well as gemcitabine, reinforcing its potential to improve outcomes in KRAS-mutated pancreatic cancer and other cancers treated with similar therapies. Significant new preclinical results demonstrate synergistic activity of SIL-204 with 5-fluorouracil and irinotecan as well as gemcitabine, reinforcing its potential to improve outcomes in KRAS-mutated pancreatic cancer and other cancers treated with similar therapies.
Neutral
GlobeNewsWire
1 month ago
Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium
Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science in the field of GI cancers Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science in the field of GI cancers
Neutral
Business Wire
2 months ago
PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises
LONDON--(BUSINESS WIRE)---- $AMGN #biotech--PESG Research Releases an Market Update Report on Silexion Therapeutics (NASDAQ: SLXN). The precision oncology sector has rapidly evolved into one of the most dynamic areas of cancer treatment innovation. Among the key players pioneering novel approaches is Silexion Therapeutics, a clinical-stage biotechnology company focused on RNA interference (RNAi) therapies for KRAS-driven cancers—one of the most prevalent and historically “undruggable” oncogenic drivers. Silexion'.
Charts implemented using Lightweight Charts™